CLINICAL APPLICATIONS OF INJECTABLE PLATELET RICH FIBRIN (IPRF) IN ADJUVANT THERAPY FOR PERIODONTITIS: A CASE SERIES

Abstract

The purpose of this study is to evaluate the clinical outcomes of non-surgical periodontal therapy using injectable Platelet Rich Fibrin (iPRF). Materials and Methods: In the present study, analyzed the results of treatment in 82(43 men and 39 women, aged 36 to 63 years) patients in the period from 2018 to 2023 years with periodontitis stages I–II were included. The following clinical parameters were recorded at the beginning of the study (before and treatment), after 1 month (after iPRF therapy), at the end of the 3-month (after iPRF therapy). The diagnosis of periodontitis was established taking radiological signs of bone loss and indicators of bleeding on probing (BOP), probing depth (PD), Clinical attachment level (CAL). All patients subjected to the complex periodontal treatment included supragingival and subgingival scaling and root debridement with an ultrasonic device, antibacterial therapy. After 4 weeks, only those patients underwent I-PRF therapy who maintained optimal oral hygiene. I PRF was injected into the gum area. The number of plasma-based sessions is strictly individual and depends on the severity of the inflammatory process (4-6 sessions break between sessions 1 week). Results: The postoperative periods in all patients passed without complications, there were no serious intraoperative or immediate postoperative complications. After a course of I-PRF therapy, patients noted elimination of pain, bleeding and swelling of the gums, tooth mobility became less bad breath disappeared, loss of bone tissue stopped. The first changes in the gums are noticeable on the 7th-10th day. The clinical picture and diagnostic parameters were comparable at baseline and after treatment. The clinical periodontal parameters (BOP, PPD, CAL) were shown a reduction in their mean values after 3 months from the treatment with the PRP, with a highly significant difference no complications had been observed. The mean value BOP before treatment was 2.6 ± 0.32, after 1month treatment the mean BOP 1.8 ± 0.2, after 3 months treatment the mean BOP 1.4 ± 0.15. The mean value PPD before treatment was 5.41 ± 0.77 mm, 1 month after therapy it was 4,27 ±0.38 mm and 3 month after therapy it was 2.46 ± 0.42 mm. The mean value CAL before treatment was 5.84 ± 0.79 mm, 1 month after therapy it was was 4.92 ± 0.71 mm. and 3 months after therapy it was 3,4 ± 0,7 mm. Conclusion: This study confirmed that iPRF periodontal therapy can be successfully used in patients diagnosed with I-II periodontitis who have received individualization supportive periodontal therapy and regular periodontal maintenance. The use of iPRF in periodontal therapy represents a valuable minimally invasive adjunct to complex conservative therapy.